Overview

Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA

Status:
Withdrawn
Trial end date:
2021-09-08
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to conduct a trial in a selected population of patients with PBC based on an incomplete biochemical response after 12 months of UDCA therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beijing 302 Hospital
Treatments:
Fenofibrate
Ursodeoxycholic Acid